evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

315 questions · 326 findings · 28 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 78 · 23.9%GRADE not reported 15 · 4.6%Very low 77 · 23.6%Low 76 · 23.3%Moderate 65 · 19.9%High 15 · 4.6%

IVIg vs PE

Number improved by 1 or more disability grades after 4 weeks · patients with Guillain‐Barré syndrome

IVIg showed no clear difference in number improved by 1 or more disability grades after 4 weeks compared with PE (moderate certainty).

1 finding from 1 review

IVIg vs PE

Dead or disabled after 12 months (48 weeks) · patients with Guillain‐Barré syndrome

IVIg showed no clear difference in dead or disabled after 12 months (48 weeks) compared with PE (low certainty).

1 finding from 1 review

IVIg vs PE

Relapse or treatment‐related fluctuation · patients with Guillain‐Barré syndrome

IVIg showed no clear difference in relapse or treatment‐related fluctuation compared with PE (low certainty).

1 finding from 1 review

IVIg vs PE

Patients in whom treatment was discontinued · patients with Guillain‐Barré syndrome

IVIg leads to lower participants in whom treatment was discontinued compared with PE (high certainty).

1 finding from 1 review

IVIg vs PE

Number of patients with adverse events attributed to treatment · patients with Guillain‐Barré syndrome

IVIg showed no clear difference in number of participants with adverse events attributed to treatment compared with PE (moderate certainty).

1 finding from 1 review

Monoclonal antibodies vs placebo

Anti‐endotoxin ‐ HA‐1A versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock

It is very uncertain whether monoclonal antibodies changes anti‐endotoxin ‐ HA‐1A versus placebo, all‐cause mortality compared with placebo (very low certainty).

3 findings from 1 review

Monoclonal antibodies vs placebo

All‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs incretin‐based control [d. 52 weeks to... · patients with sepsis, severe sepsis, septic shock

Monoclonal antibodies showed no clear difference in anti‐endotoxin, all‐cause mortality ‐ unclear risk of bias compared with placebo (moderate certainty).

1 finding from 1 review

Monoclonal antibodies vs placebo

Anti‐cytokine, all‐cause mortality ‐ uncertain risk of bias · patients with sepsis, severe sepsis, septic shock

Monoclonal antibodies probably leads to lower anti‐cytokines versus placebo, all‐cause mortality compared with placebo (moderate certainty).

3 findings from 1 review

Monoclonal antibodies vs placebo

Anticytokine ‐ anti‐TNF‐alpha versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock

Monoclonal antibodies probably leads to lower anticytokine ‐ anti‐TNF‐alpha versus placebo, all‐cause mortality compared with placebo (moderate certainty).

1 finding from 1 review

Monoclonal antibodies vs placebo

Anti‐cytokines ‐ human interleukin‐1receptor antagonist versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock

Monoclonal antibodies showed no clear difference in anti‐cytokines ‐ human interleukin‐1receptor antagonist versus… compared with placebo (moderate certainty).

1 finding from 1 review